NCT04455815 - A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 23, 2020

Primary Completion Date

November 29, 2021

Study Completion Date

March 3, 2022

Conditions

COVID-19 Infection

Interventions

DRUG

Camostat

Patient to receive treatment with camostat tablets, 200mg four times daily (qds) for 14 days.

Trial Locations (9)

Chawton Park Surgery, Alton

The Royal Infirmary of Edinburgh, Edinburgh

Church Avenue Medical Group, Harrogate

John Radcliffe Hospital, Oxford

Preston Lantern Centre, Preston

Clarence Medical Centre, Rhyl

Trafalgar Medical Practice, Southsea

Velindre Hospital, Wales

Eynsham Medical Centre, Witney